Dr. Cass asks about the biggest bottlenecks to starting treatment at the panelists’ own institutions.
Dr. Lynch names testing delays. Her team wants pathology reviewed internally when it was done elsewhere, along with NGS results, before starting. Strategies exist to begin chemotherapy alone and hold the checkpoint inhibitor while awaiting results. Even so, the team prefers to start the most appropriate therapy from the outset, sparing patients with a targetable mutation the side effects of chemotherapy. Some insurers will not approve a platinum doublet plus immunotherapy regimen until NGS results are back. Insufficient tissue can also force a re-biopsy.
Dr. Luon describes the same problems. Reflex testing helps, particularly for patients diagnosed within his health system. His team primarily uses Guardant and Foundation One, which help navigate the insurance approvals that NGS often requires. For outside diagnoses, new patient coordinators gather records early, even from rural practices that rely on paper charts, where NGS results may be buried in a file.
Dr. Lynch asks whether liquid biopsy is sent on every patient. Dr. Luon says a positive tissue result is enough to move forward, but pending or negative tissue results carry some risk of false negatives. Studies suggest that combining tissue and liquid testing is more effective, so his team does both. Liquid biopsy and NGS cannot be drawn until the first appointment, and he wishes patients could be tested earlier.
Dr. Cass shares that her institution tried this. After a biopsy, tissue NGS triggered a mobile phlebotomy order for liquid biopsy. Patients were confused, and staff spent considerable effort contacting people they had never seen, because the order came through medical oncology. The program became too burdensome, so the team stopped. She would still welcome a smooth process, perhaps involving a virtual appointment.
In “Squamous vs Non-Squamous NSCLC: Do Treatment Pathways and Monitoring Differ?,” the panel will examine whether pathways and monitoring differ by histology.
